Reading Arcus’s Tigit tea leaves
As data non-disclosure prompts sellside guesswork one indisputable fact stands out: Gilead has not opted in to Arcus’s domvanalimab.
Spac sparkle wins over health techs
Large numbers of blank-cheque groups are seeking deals, but the bloom might be coming off the rose.
23andme joins health tech’s Spacmania
But more traditional device makers seem uninterested in this means of stock market listing.
How machines could mine forgotten data
Drug discovery is getting harder, and some companies are turning to machine learning to look for new targets.
Glaxo needs acquisitions to become a big deal in oncology
Glaxosmithkline is trying to reinvent itself as an oncology company – but it will need to make bolder deals if it wants to succeed.